CATPB

Last updated
CATPB
CATPB structure.png
Identifiers
  • (3S)-3-[[2-(3-chlorophenyl)acetyl]amino]-4-[4-(trifluoromethyl)phenyl]butanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
Chemical and physical data
Formula C19H17ClF3NO3
Molar mass 399.79 g·mol−1
3D model (JSmol)
  • C1=CC(=CC(=C1)Cl)CC(=O)N[C@@H](CC2=CC=C(C=C2)C(F)(F)F)CC(=O)O
  • InChI=1S/C19H17ClF3NO3/c20-15-3-1-2-13(8-15)10-17(25)24-16(11-18(26)27)9-12-4-6-14(7-5-12)19(21,22)23/h1-8,16H,9-11H2,(H,24,25)(H,26,27)/t16-/m0/s1
  • Key:QOSIJVVNNGXEKE-INIZCTEOSA-N

CATPB is an experimental drug which acts as a potent and selective antagonist for the free fatty acid receptor FFAR2 (GPR43), and is used for research into the function of this receptor. [1] [2] [3] [4] [5] [6]

References

  1. ↑ Park BO, Kim SH, Kong GY, Kim DH, Kwon MS, Lee SU, et al. (January 2016). "Selective novel inverse agonists for human GPR43 augment GLP-1 secretion". European Journal of Pharmacology. 771: 1–9. doi:10.1016/j.ejphar.2015.12.010. PMID   26683635.
  2. ↑ Mårtensson J, Holdfeldt A, Sundqvist M, Gabl M, Kenakin TP, Björkman L, et al. (December 2018). "Neutrophil priming that turns natural FFA2R agonists into potent activators of the superoxide generating NADPH-oxidase". Journal of Leukocyte Biology. 104 (6): 1117–1132. doi:10.1002/JLB.2A0318-130RR. PMID   30134499.
  3. ↑ Højgaard Hansen A, Christensen HB, Pandey SK, Sergeev E, Valentini A, Dunlop J, et al. (November 2021). "Structure-Activity Relationship Explorations and Discovery of a Potent Antagonist for the Free Fatty Acid Receptor 2". ChemMedChem. 16 (21): 3326–3341. doi:10.1002/cmdc.202100356. PMID   34288488.
  4. ↑ Miyasato S, Iwata K, Mura R, Nakamura S, Yanagida K, Shindou H, et al. (January 2023). "Constitutively active GPR43 is crucial for proper leukocyte differentiation". FASEB Journal. 37 (1): e22676. doi: 10.1096/fj.202201591R . PMID   36468834.
  5. ↑ Valentini A, Schultz-Knudsen K, Højgaard Hansen A, Tsakoumagkou A, Jenkins L, Christensen HB, et al. (May 2023). "Discovery of Potent Tetrazole Free Fatty Acid Receptor 2 Antagonists". Journal of Medicinal Chemistry. 66 (9): 6105–6121. doi:10.1021/acs.jmedchem.2c01935. PMC   10547238 . PMID   37129317.
  6. ↑ Muradás TC, Freitas RD, Gonçalves JI, Xavier FA, Marinowic DR (2024). "Potential antitumor effects of short-chain fatty acids in breast cancer models". American Journal of Cancer Research. 14 (5): 1999–2019. doi:10.62347/ETUQ6763. PMC   11162650 . PMID   38859825.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.